EGFR and non-small cell lung carcinoma: According to randomized clinical trials on EGFR - TKI for unresectable advanced non-small-cell lung cancer, progression-free survival and overall survival were reported to be 9.2–11.0 months and 19.3–34.8 months, respectively [1–3].